Imatinib (CML chronic phase 1L)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-IMATINIB |
|---|
| ID | REG-IMATINIB-CML |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ELN-CML-2020 SRC-ESMO-CML-2017 SRC-IRIS-OBRIEN-2003 SRC-NCCN-MPN-2025 |
Notes
Standard 1L for low-risk CML chronic phase, elderly, comorbid patients, or where cost / access is limiting. IRIS established imatinib 400 mg daily; 10-y OS ~83%. ELN 2020 milestones: ≤10% at 3 mo, ≤1% at 6 mo, ≤0.1% (MMR) at 12 mo. PCR monitoring q3mo for first year, then q3-6mo. TFR attempt eligible after ≥3 years on TKI + sustained DMR (MR4.5) ≥2 years per ELN. STUB — requires clinical co-lead signoff before publication.
Used By
Indication
IND-CML-1L-IMATINIB- IND-CML-1L-IMATINIB